Expression of HCV Alternative Reading Frame Protein (Core+1/F) in Baculovirus Expression System and its Evaluation for Assessment of Specific Anti-core+1 Antibody in Iranian HCV Infected Patients

Rahimi, P; Vahabpour, Rouhollah; Fard, Farideh Sadat Sajadian; Motevalli, Fatemeh; Chahouki, Fatemeh Fotouhi; Aghasadeghi, Mohammad Reza; Bolhassani, Azam; Sadat, Seyed Mehdi; Mostafavi, Ehsan; Mohajel, Nasir; Jahanian-Najafabadi, Ali; Amiran, Mohammad Reza

doi:10.7754/clin.lab.2016.160205

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, there was a significant change in the titer of anti-core+1 Abs during the combination therapy in responder patients compared to non-responder individuals, which was in accordance with some reports showing a link between the immune response to core+1 protein, manifested by the development of anti-core+1 Abs, and the outcome of combination therapy (5,6,11,13,17). In detail, Gao et al (17) fected with HCV receiving antiviral therapy, all of the patients with negative anti-core+1 Ab at the baseline and 70% of anti-core+1 Ab positive patients achieved SVR.…”

Section: Discussionsupporting

confidence: 79%

“…There are some reports indicating that chronic hepatitis C (CHC) infection is strongly associated with hepatocellular carcinoma (HCC) (3)(4)(5)(6)(7)(8)(9). There is neither effective vaccine for immunization, nor a broadly effective treatment for HCV infection (3).Among different factors associated with chronic HCV infection, alternate reading frame protein (ARFP) or core+1 protein is one the newest ones that can promote persistent infection (10)(11)(12). This protein is produced by a frame shift at codon 11 by a minority of ribosomes that initiate translation at the HCV AUG initiator codon of HCV genome (13,14).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Decline in Anti-Core+1 Antibody Titer Occurs in Successful Treatment of Patients Infected with Hepatitis C Virus

Hashempoor¹,

Alborzi²,

Moayedi³

et al. 2018

Jundishapur J Microbiol

View full text Add to dashboard Cite

Background: Hepatitis C virus (HCV) causes one of the major chronic liver diseases (CLD). HCV-core encoding sequence possesses an overlapping open reading frame (ORF) that expresses a protein called F or core+1. Objectives: The current study aimed at assessing the presence and titer of anti-core+1 antibody (Ab) in 70 Iranian patients infected with HCV-1a, responder and non-responder groups, under combination therapy with pegylated interferon-α (PegIFN-α) plus ribavirin (RBV) using an enzyme-linked immunosorbent assay (ELISA). Methods: In the current cohort study, HCV-1a core+1 gene was amplified and cloned into vector followed by expressing in Escherichia coli and then, purified by ion exchange chromatography. The antibody titer of patients was evaluated before, during (12, 24, and 48 weeks), and 6 months after the end of therapy (ETR). Results: The seroprevalence of anti-core+1 Ab was 75.7% in pretreatment sera. The combination therapy could induce a decline in the level of anti-core+1 Ab in both groups of responders and non-responders. These changes were significant only in the responders (P = 0.003). The seroprevalence of anti-core+1 Ab had no correlation with the outcome of treatment. Conclusions: According to the current study results, HCV core+1 protein elicit a specific antibody response other than the anti-core protein antibodies. The current study data also suggested that the level of anti-core+1 antibody might be affected by the combination therapy and associated with sustained virological response (SVR). The data implied that the declining trend of anti-core+1 Abs during the treatment might be an alternative representation of the therapeutic response in Iranian population infected with HCV.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Introductionmentioning

confidence: 99%

A Decline in Anti-Core+1 Antibody Titer Occurs in Successful Treatment of Patients Infected with Hepatitis C Virus

Hashempoor¹,

Alborzi²,

Moayedi³

et al. 2018

Jundishapur J Microbiol

View full text Add to dashboard Cite

show abstract

Expression of HCV Alternative Reading Frame Protein (Core+1/F) in Baculovirus Expression System and its Evaluation for Assessment of Specific Anti-core+1 Antibody in Iranian HCV Infected Patients

Abstract: HCV core+1 protein was expressed successfully in a baculovirus expression system in high yield in order to develop an ELISA to assess the anti-core+1 antibody. Further studies are needed to reveal the potential application of core+1 protein in anti-HCV treatment prognosis.

Cited by 1 publication

References 0 publications

A Decline in Anti-Core+1 Antibody Titer Occurs in Successful Treatment of Patients Infected with Hepatitis C Virus

A Decline in Anti-Core+1 Antibody Titer Occurs in Successful Treatment of Patients Infected with Hepatitis C Virus

Contact Info

Product

Resources

About